EMA: Multiple COVID-19 Booster Programs ‘Not Sustainable’ In Long Term
Agency Sees No Evidence Of Vaccine Risk In Pregnancy
Global regulators have been discussing how best to approach vaccination in the face of possible future coronavirus variants, and whether bivalent or multivalent vaccines could be the answer.
You may also be interested in...
Coronavirus Notebook: Australia OKs Paxlovid, Lagevrio & Nuvaxovid, New Sputnik Data Show ‘Strong Protection’ Against Omicron
International regulators have broadened their discussions on the possible use of bivalent and multivalent vaccines, and the French presidency of the Council of the EU has called for “international solidarity” on vaccine provision.
Five vaccines and six therapeutics are now available for use against COVID-19 in the EU, but as Omicron shows, there is likely to be a need for new kinds of vaccines against future virus variants.
With efforts continuing to maximize access to medical countermeasures against the pandemic threat, a webinar organized by NGOs looked at progress with and the shortcomings of the WHO’s C-TAP initiative, recent moves by the WHO on access provisions in funding agreements, and plans for a global C-TAP database.